Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ovid Therapeutics Inc.OVID · Entity 5411 | Director | June 15, 2026 | June 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ovid Therapeutics Inc.
Report date June 15, 2026 · Filed June 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.26 · Expires 2036-06-14 | Direct | 130,000 |
Reported balance
After 2026-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-15 · Grant · Acquired 130,000 · Balance 130,000 F1: The shares subject to the stock option will vest in 36 equal monthly installments commencing on July 15, 2026, subject to the Reporting Person's continued services through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the stock option will vest in 36 equal monthly installments commencing on July 15, 2026, subject to the Reporting Person's continued services through each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 15, 2026 Filed Jun 17, 2026 20:22 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | GrantStock Option (right to buy) · Derivative | 130,000 | $0.00 Strike: $2.26 | $0.00 |
DisclosureSEC source: 0002138163-26-000005 · form4-06172026_080618.xml · derivative · entry 1 Greka Anna · CIK 0002138163 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires 2036-06-14 F1 · derivative.exercise_date: The shares subject to the stock option will vest in 36 equal monthly installments commencing on July 15, 2026, subject to the Reporting Person's continued services through each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.